Business Wire

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly

22.5.2026 13:45:00 CEST | Business Wire | Press Release

Share

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/

Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve.

Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the same time, access to prevention remains unequal, with underserved communities often facing the greatest barriers to early screening and timely care, as well as reliable health information. The Future Health Challenge focused on solutions designed to detect health risks sooner, monitor population-level data, and support faster decision-making by health authorities.

Five finalist teams presented their solutions to an international audience spanning global health, philanthropy, investment, technology and life sciences, with the judging team awarding prizes to the following teams:

  • ThinkMD, Australia
    USD 200,000, Winner
    ThinkMD equips frontline health workers with mobile clinical decision-support tools that improve triage, treatment, and referral, while turning routine care encounters into real-time population health signals. The platform is already used by more than 9,000 frontline workers across 885 facilities, with the platform’s ability to act as an early warning system demonstrated through previously detected symptom patterns preceding a cholera outbreak in Zambia.

  • Vector Control Innovations, United States
    USD 50,000, Distinguished Finalist
    VectorCam uses AI-enabled mosquito surveillance to detect changing vector risks earlier, helping health systems target interventions before outbreaks escalate. Field evaluations of VectorCam’s impact have shown clear improvements in both efficiency and data quality, with evaluations showing data completeness increasing from around 60% to over 90%.

  • Huna, Brazil
    USD 50,000, Distinguished Finalist
    Huna applies AI to routine blood test data to identify people at elevated cancer risk earlier and guide them into appropriate screening and care pathways. In Brazil, its pilots have screened more than 500,000 patients, and across all deployments to date, hundreds of cancer cases have been detected, many of which would likely have been found later when treatment is more complex and expensive.

Delivered in collaboration with MIT Solve, the Future Health Challenge is part of Future Health’s year-round programme of activities designed to identify and champion high-potential talent globally, connecting innovators with funding, partnerships and pathways to scale solutions that advance longer, healthier lives.

Dr. Jackie Rabec, Co-Founder of ThinkMD, said: “We are thrilled to be the recipients of this award, and we are excited to be able to use it to scale our impact. Our next stage of growth will be expanding in priority markets across Nigeria, Rwanda, Uganda and Somalia, validating our next generation multimodal conversational interface and furthering our self-care product to deliver health intelligence into the hands of citizens.”

Dr. Asma Al Mannaei, Executive Director of the Health and Life Sciences Sector at the Department of Health – Abu Dhabi said “Too often, health systems only detect risk once it has become illness, when treatment is more complex and outcomes are worse. Solutions from the Future Health Challenge are designed to identify risk earlier and support more timely decisions at a population level. The priority now is testing and scaling what works in real-world settings.”

Hala Hanna, Executive Director of MIT Solve, said: “The solutions emerging from this Challenge reflect both the urgency and the opportunity facing health systems globally. By bringing innovators together with policymakers, funders and implementers through platforms such as Future Health, we can help accelerate solutions that are locally grounded and capable of delivering impact at scale.”

MIT Solve has more than a decade of experience in delivering global innovation challenges across health, climate, learning and economic prosperity. To date, MIT Solve has mobilised over USD 80 million in funding for innovators worldwide, with supported solutions reaching more than 370 million lives.

The Challenge forms part of Future Health’s purpose to identify and support innovations that improve health outcomes. Beyond prize funding, participating teams will be connected to partners, investors and health authorities to support the next phase of development and adoption.

Representatives from finalist, semi-finalist and selected Honourable Mention teams will also be invited to showcase their innovations at the Abu Dhabi Future Health Summit, taking place from 20 to 22 October 2026.

Future Health continues to advance a year-round programme across longevity and precision medicine, intelligent health and AI, health system resilience and sustainability, and investment in life sciences, to empower better health worldwide. The platform will continue to introduce new opportunities for global collaboration and discovery of impactful solutions throughout the year.

For more information about the Future Health Challenge and upcoming programme milestones, visit www.futurehealthinitiative.ae⁠

View source version on businesswire.com: https://www.businesswire.com/news/home/20260522587414/en/

Contacts

For media inquiries, please contact media@futurehealthinitiative.ae

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press Release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press Release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press Release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press Release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press Release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye